A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and P… (NCT07678593) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Australia, China222 participantsStarted 2026-09
Plain-language summary
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥ 18 years
. Histologically or cytologically confirmed locally advanced or metastatic solid tumor and PDAC with RAS mutation or KRAS amplification
. At least one measurable lesion according to RECIST v1.1
. ECOG performance status 0 or 1
. Life expectancy \> 3 months
. Adequate organ function
. Willing to provide written informed consent
. Fertile participants must use effective contraception
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Phase Ib:Incidence of Dose-Limiting Toxicity (DLT) Events
Timeframe: First 28 days (21 days for AG （3-week cycle）)
2
Phase Ib:Incidence and Severity of Adverse Events (AE) and Serious Adverse Events (SAE)
Timeframe: From the first dose until 30 days after the last dose, assessed up to 24 months
3
Phase II:Objective Response Rate (ORR)
Timeframe: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
4
Phase Ib: Number of participants with abnormality in hematology laboratory parameters
Timeframe: up to 24 months
5
Phase Ib: Number of participants with abnormality in clinical chemistry laboratory assessments
Timeframe: up to 24 months
6
Phase Ib: Number of participants with abnormality in body temperature